JP2015528454A5 - - Google Patents

Download PDF

Info

Publication number
JP2015528454A5
JP2015528454A5 JP2015529009A JP2015529009A JP2015528454A5 JP 2015528454 A5 JP2015528454 A5 JP 2015528454A5 JP 2015529009 A JP2015529009 A JP 2015529009A JP 2015529009 A JP2015529009 A JP 2015529009A JP 2015528454 A5 JP2015528454 A5 JP 2015528454A5
Authority
JP
Japan
Prior art keywords
vegf antagonist
medicament
administered
antibody
medicament according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015529009A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015528454A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/067846 external-priority patent/WO2014033184A1/en
Publication of JP2015528454A publication Critical patent/JP2015528454A/ja
Publication of JP2015528454A5 publication Critical patent/JP2015528454A5/ja
Pending legal-status Critical Current

Links

JP2015529009A 2012-08-28 2013-08-28 眼血管増殖性疾患の処置におけるｖｅｇｆアンタゴニストの使用 Pending JP2015528454A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261693913P 2012-08-28 2012-08-28
US61/693,913 2012-08-28
PCT/EP2013/067846 WO2014033184A1 (en) 2012-08-28 2013-08-28 Use of a vegf antagonist in treating ocular vascular proliferative diseases

Publications (2)

Publication Number Publication Date
JP2015528454A JP2015528454A (ja) 2015-09-28
JP2015528454A5 true JP2015528454A5 (https=) 2016-11-24

Family

ID=49083670

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015529009A Pending JP2015528454A (ja) 2012-08-28 2013-08-28 眼血管増殖性疾患の処置におけるｖｅｇｆアンタゴニストの使用

Country Status (4)

Country Link
US (1) US20150297675A1 (https=)
EP (1) EP2890389A1 (https=)
JP (1) JP2015528454A (https=)
WO (1) WO2014033184A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2494108C2 (ru) 2006-04-07 2013-09-27 Аерпио Терапетикс, Инк. Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование
WO2013056240A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
EP3010526A1 (en) * 2013-06-20 2016-04-27 Novartis AG Use of a vegf antagonist in treating macular edema
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
CN108290004A (zh) * 2015-11-18 2018-07-17 福尔密孔股份公司 含有vegf拮抗剂的预填充塑料注射器
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
CN108697772B (zh) 2015-12-30 2022-06-24 马歇尔大学科研协会 用于治疗视网膜病的组合物和方法
US10576128B2 (en) * 2016-01-26 2020-03-03 Formycon Ag Liquid formulation of a VEGF antagonist
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
MY202872A (en) * 2017-11-20 2024-05-28 Just Evotec Biologics Inc Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
KR20200131839A (ko) * 2018-03-16 2020-11-24 노파르티스 아게 안질환의 치료 방법
KR102038008B1 (ko) * 2018-04-03 2019-10-29 주식회사 루트로닉 안과용 치료장치 및 이의 제어방법
WO2020068653A1 (en) * 2018-09-24 2020-04-02 Aerpio Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
EP4028015A4 (en) * 2019-09-13 2023-11-15 Aldeyra Therapeutics, Inc. Ophthalmic formulations of methotrexate
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
MX2022015651A (es) 2020-06-11 2023-01-16 Genentech Inc Conjugados de nanolipoproteina-polipeptido y composiciones, sistemas y procedimientos mediante el uso de los mismos.
WO2023019216A2 (en) * 2021-08-13 2023-02-16 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and treating ischemic eye disease
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
US11911385B1 (en) 2022-12-14 2024-02-27 Aldeyra Therapeutics, Inc. Methotrexate treatment methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003066824A2 (en) * 2002-02-07 2003-08-14 Aventis Behring Gmbh Albumin-fused kunitz domain peptides
US7399612B2 (en) * 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US11078262B2 (en) * 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
WO2010005527A1 (en) * 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
BRPI0921469B1 (pt) * 2008-11-03 2022-01-18 Molecular Partners Ag Proteínas de ligação que inibem a interação com o receptor de vegf-a, composição farmacêutica
SG176202A1 (en) * 2009-05-28 2011-12-29 Glaxo Group Ltd Combination of a tnf-alpha antagonist and a vegf antagonist for use in the treatment or prevention of diseases of the eye.
EP2671589A4 (en) * 2011-02-02 2014-11-19 Public Univ Corp Nagoya City Univ MEDICAMENT FOR PREVENTING OR TREATING DISEASES RELATED TO INTRAOCULAR NEOVASCULARIZATION AND / OR INTRAOCULAR VASCULAR HYPERPERMEABILITY

Similar Documents

Publication Publication Date Title
JP2015528454A5 (https=)
JP2012525415A5 (https=)
JP2016528202A5 (https=)
KR102373289B1 (ko) 지속성 부종을 갖는 삼출성 노인성 황반변성을 치료하기 위한 시롤리무스의 용도
JP2012072152A5 (https=)
US11478465B2 (en) Compounds for treatment of eye diseases associated with excessive vascularisation
WO2014033184A1 (en) Use of a vegf antagonist in treating ocular vascular proliferative diseases
JP2014532072A5 (https=)
ME00591B (me) Upotreba dii4 antagonista kod ishemijske povrede ili vaskularne insuficijencije
JP2017537105A5 (https=)
JP5557408B1 (ja) 眼底疾患治療剤
JP2019510078A5 (https=)
CN114306575A (zh) 具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗
JP2017525769A5 (https=)
JP2012505162A5 (https=)
Tomomatsu et al. Comparative study of combined bevacizumab/targeted photocoagulation vs bevacizumab alone for macular oedema in ischaemic branch retinal vein occlusions
Fang et al. Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema
PH12020551015A1 (en) Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability
JP2016516761A5 (https=)
US20170224815A1 (en) Method of Preventing and Treating Retinal Microvasculature Inflammation Using C-Met Signaling Pathway Inhibition
KR20160013026A (ko) 폴립양 맥락막 혈관병증의 치료
Khan et al. Interferon associated retinopathy
SHARM et al. Clinical Utilisation of Bevacizumab and Patient Monitoring in Retinal Vein Occlusion and Diabetic Macular Edema
Tataru et al. Evaluation of the efficacy and safety of intravitreal bevacizumab for macular edema related to retinal vein occlusion
KR20260019535A (ko) 보체 항체-약물 접합체